دورية أكاديمية
أعرض في EDS

Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy.

التفاصيل البيبلوغرافية
العنوان: Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy.
المؤلفون: Wee Y; Department of Pathology, University of Utah, Salt Lake City, UT, USA.; Huntsman Cancer Institute, Salt Lake City, UT, USA.; School of Dentistry, Taipei Medical University, Taipei, Taiwan., Wang J; Huntsman Cancer Institute, Salt Lake City, UT, USA.; Department of Oncologic Sciences, University of Utah, Salt Lake City, UT, USA., Wilson EC; Department of Pathology, University of Utah, Salt Lake City, UT, USA.; Huntsman Cancer Institute, Salt Lake City, UT, USA., Rich CP; Department of Pathology, University of Utah, Salt Lake City, UT, USA.; Huntsman Cancer Institute, Salt Lake City, UT, USA., Rogers A; Department of Pathology, University of Utah, Salt Lake City, UT, USA.; Huntsman Cancer Institute, Salt Lake City, UT, USA., Tong Z; Department of Pathology, University of Utah, Salt Lake City, UT, USA., DeGroot E; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gopal YNV; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ekiz HA; Department of Molecular Biology and Genetics, Izmir Institute of Technology, Gulbahce, Urla, Izmir, Turkey., Tay JKH; Department of Pathology, University of Utah, Salt Lake City, UT, USA.; Huntsman Cancer Institute, Salt Lake City, UT, USA., Stubben C; Bioinformatics Shared Resource, Huntsman Cancer Institute, Salt Lake City, UT, USA., Boucher KM; Cancer Biostatistics Shared Resource, Huntsman Cancer Institute, Salt Lake City, UT, USA., Oviedo JM; Department of Pathology, University of Utah, Salt Lake City, UT, USA., Fairfax KC; Department of Pathology, University of Utah, Salt Lake City, UT, USA., Williams MA; Department of Pathology, University of Utah, Salt Lake City, UT, USA.; Huntsman Cancer Institute, Salt Lake City, UT, USA., Holmen SL; Huntsman Cancer Institute, Salt Lake City, UT, USA.; Department of Oncologic Sciences, University of Utah, Salt Lake City, UT, USA.; Department of Surgery, University of Utah, Salt Lake City, UT, USA., Wolff RK; Department of Pathology, University of Utah, Salt Lake City, UT, USA.; Huntsman Cancer Institute, Salt Lake City, UT, USA., Grossmann AH; Department of Pathology, University of Utah, Salt Lake City, UT, USA. allie.grossmann@providence.org.; Huntsman Cancer Institute, Salt Lake City, UT, USA. allie.grossmann@providence.org.; Department of Oncologic Sciences, University of Utah, Salt Lake City, UT, USA. allie.grossmann@providence.org.; Providence Cancer Institute of Oregon, Earle A. Chiles Research Institute, Portland, OR, USA. allie.grossmann@providence.org.
المصدر: Nature communications [Nat Commun] 2024 Aug 04; Vol. 15 (1), pp. 6613. Date of Electronic Publication: 2024 Aug 04.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: Tumor Microenvironment*/immunology , ADP-Ribosylation Factor 6* , ADP-Ribosylation Factors*/metabolism , ADP-Ribosylation Factors*/genetics , Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/therapeutic use , Melanoma*/genetics , Melanoma*/drug therapy , Melanoma*/metabolism , Melanoma*/pathology , Melanoma*/immunology , Cell Membrane*/metabolism, Animals ; Humans ; Mice ; Cell Line, Tumor ; Interferon gamma Receptor ; Receptors, Interferon/metabolism ; Receptors, Interferon/genetics ; Protein Transport ; Melanoma, Experimental/immunology ; Melanoma, Experimental/metabolism ; Melanoma, Experimental/pathology ; Melanoma, Experimental/genetics ; Mice, Inbred C57BL ; Female
مستخلص: Tumour-host immune interactions lead to complex changes in the tumour microenvironment (TME), impacting progression, metastasis and response to therapy. While it is clear that cancer cells can have the capacity to alter immune landscapes, our understanding of this process is incomplete. Herein we show that endocytic trafficking at the plasma membrane, mediated by the small GTPase ARF6, enables melanoma cells to impose an immunosuppressive TME that accelerates tumour development. This ARF6-dependent TME is vulnerable to immune checkpoint blockade therapy (ICB) but in murine melanoma, loss of Arf6 causes resistance to ICB. Likewise, downregulation of ARF6 in patient tumours correlates with inferior overall survival after ICB. Mechanistically, these phenotypes are at least partially explained by ARF6-dependent recycling, which controls plasma membrane density of the interferon-gamma receptor. Collectively, our findings reveal the importance of endomembrane trafficking in outfitting tumour cells with the ability to shape their immune microenvironment and respond to immunotherapy.
(© 2024. The Author(s).)
References: Immunity. 2023 Oct 10;56(10):2270-2295. (PMID: 37820584)
PLoS One. 2011;6(9):e25301. (PMID: 21966491)
Small GTPases. 2019 Jan;10(1):1-12. (PMID: 28001501)
J Immunol. 2021 Jan 15;206(2):366-375. (PMID: 33310872)
Immunity. 2018 Mar 20;48(3):399-416. (PMID: 29562192)
Cancer Cell. 2016 Jun 13;29(6):889-904. (PMID: 27265506)
Cell Rep. 2015 Oct 13;13(2):412-24. (PMID: 26411680)
Mol Cell Biol. 2013 Aug;33(15):2963-75. (PMID: 23716594)
J Clin Invest. 2018 May 1;128(5):2048-2063. (PMID: 29664013)
Cell Rep. 2015 Nov 3;13(5):898-905. (PMID: 26565903)
Proc Natl Acad Sci U S A. 2019 Aug 27;116(35):17450-17459. (PMID: 31399545)
Nat Immunol. 2019 Feb;20(2):163-172. (PMID: 30643263)
Eur J Cancer. 2021 Jul;152:165-182. (PMID: 34107450)
Front Mol Neurosci. 2016 Jun 23;9:46. (PMID: 27445685)
Nat Rev Mol Cell Biol. 2011 Jun;12(6):362-75. (PMID: 21587297)
Bioinformatics. 2014 Apr 1;30(7):923-30. (PMID: 24227677)
Cancer Res. 2019 Jun 1;79(11):2892-2908. (PMID: 31048499)
J Cell Biol. 2003 Dec 8;163(5):1111-21. (PMID: 14662749)
Nat Commun. 2017 Mar 10;8:14688. (PMID: 28281543)
BMC Bioinformatics. 2013 Apr 15;14:128. (PMID: 23586463)
Cancer Res. 2021 Dec 13;:. (PMID: 34903605)
Nat Rev Immunol. 2022 Mar;22(3):158-172. (PMID: 34155388)
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9671-6. (PMID: 15210957)
Curr Biol. 2009 Dec 1;19(22):1875-85. (PMID: 19896381)
Sci Signal. 2013 Mar 05;6(265):ra14. (PMID: 23462101)
FEBS Lett. 2006 Feb 6;580(3):755-62. (PMID: 16413538)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
J Clin Oncol. 2013 Nov 20;31(33):4252-9. (PMID: 24127443)
Cancer Discov. 2021 Apr;11(4):933-959. (PMID: 33811125)
Cell Mol Life Sci. 2023 Mar 14;80(4):87. (PMID: 36917255)
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7444-8. (PMID: 17460038)
Genome Biol. 2019 Dec 23;20(1):296. (PMID: 31870423)
Nat Rev Immunol. 2021 Aug;21(8):485-498. (PMID: 33526920)
J Cell Biol. 2000 Oct 30;151(3):627-38. (PMID: 11062263)
Cancer Discov. 2022 Jun 2;12(6):1518-1541. (PMID: 35404441)
Cell. 2021 Jun 24;184(13):3573-3587.e29. (PMID: 34062119)
Cancer Res. 2009 Mar 15;69(6):2201-9. (PMID: 19276388)
Nature. 2012 Dec 13;492(7428):252-5. (PMID: 23143332)
Cancer Discov. 2015 Sep;5(9):915-9. (PMID: 26272491)
Anticancer Res. 1986 Sep-Oct;6(5):877-84. (PMID: 2432832)
J Biol Chem. 1996 Sep 6;271(36):21767-74. (PMID: 8702973)
J Cell Biol. 1998 Feb 9;140(3):603-16. (PMID: 9456320)
Trends Cancer. 2023 Mar;9(3):198-211. (PMID: 36593148)
Mol Biol Cell. 2019 May 15;30(11):1249-1271. (PMID: 31084567)
Cancer Res. 2009 Feb 1;69(3):794-801. (PMID: 19155310)
J Clin Oncol. 2012 Aug 10;30(23):2912-8. (PMID: 22778321)
Cell. 2015 Jun 18;161(7):1681-96. (PMID: 26091043)
EMBO J. 2001 Sep 3;20(17):4973-86. (PMID: 11532961)
Cancer Res. 1990 Dec 1;50(23):7422-9. (PMID: 1701342)
Bioinformatics. 2016 Oct 1;32(19):3047-8. (PMID: 27312411)
Curr Biol. 2007 Apr 17;17(8):722-7. (PMID: 17398097)
Nat Cancer. 2023 Sep;4(9):1258-1272. (PMID: 37537301)
J Immunol. 2010 Sep 15;185(6):3190-8. (PMID: 20720200)
J Biol Chem. 2000 Feb 4;275(5):3221-30. (PMID: 10652308)
J Clin Invest. 2017 Dec 1;127(12):4569-4582. (PMID: 29058688)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Semin Cell Dev Biol. 2011 Feb;22(1):39-47. (PMID: 20837153)
Nat Rev Drug Discov. 2022 Jul;21(7):529-540. (PMID: 35701637)
Nat Commun. 2021 May 20;12(1):2965. (PMID: 34017005)
Nat Commun. 2018 Jul 11;9(1):2682. (PMID: 29992963)
Cell. 2019 Aug 8;178(4):933-948.e14. (PMID: 31398344)
Curr Biol. 2011 Apr 12;21(7):574-9. (PMID: 21439824)
Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204)
Nat Rev Mol Cell Biol. 2018 Nov;19(11):679-696. (PMID: 30194414)
Cell. 2010 May 28;141(5):812-21. (PMID: 20510928)
Nat Commun. 2017 Jan 16;8:14049. (PMID: 28091601)
Commun Integr Biol. 2012 Jul 1;5(4):316-8. (PMID: 23060951)
J Immunol. 1987 Jul 1;139(1):147-53. (PMID: 2953810)
Nat Cell Biol. 2008 Jan;10(1):85-92. (PMID: 18084281)
Nat Rev Drug Discov. 2022 Jul;21(7):509-528. (PMID: 34937915)
Cell. 2016 Oct 6;167(2):397-404.e9. (PMID: 27667683)
N Engl J Med. 2016 Sep 1;375(9):819-29. (PMID: 27433843)
J Immunol. 2014 Jun 15;192(12):6045-52. (PMID: 24835390)
Nat Biotechnol. 2015 May;33(5):495-502. (PMID: 25867923)
معلومات مُعتمدة: 133649RSG1901901CSM American Cancer Society (American Cancer Society, Inc.); W81XWH2210910 U.S. Department of Defense (United States Department of Defense); K08 CA188563 United States CA NCI NIH HHS; P50 CA221703 United States CA NCI NIH HHS; R01 AI158710 United States AI NIAID NIH HHS; R01 CA121118 United States CA NCI NIH HHS; R37CA230630-01A1 U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI); R37 CA230630 United States CA NCI NIH HHS; P30 CA042014 United States CA NCI NIH HHS
المشرفين على المادة: 0 (ADP-Ribosylation Factor 6)
EC 3.6.5.2 (ADP-Ribosylation Factors)
0 (Immune Checkpoint Inhibitors)
EC 3.6.5.2 (ARF6 protein, human)
EC 3.6.5.2 (Arf6 protein, mouse)
0 (Interferon gamma Receptor)
0 (Receptors, Interferon)
تواريخ الأحداث: Date Created: 20240804 Date Completed: 20240804 Latest Revision: 20240807
رمز التحديث: 20240807
مُعرف محوري في PubMed: PMC11298541
DOI: 10.1038/s41467-024-50881-1
PMID: 39098861
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-024-50881-1